Т-клеточные лимфомы кожи: современные данные патогенеза, клиники и терапии
https://doi.org/10.17650/1818-8346-2018-13-3-25-38
Аннотация
Т-клеточные лимфомы кожи (ТКЛК) представляют собой гетерогенную группу экстранодальных неходжкинских лимфом, которые характеризуются инфильтрацией кожи злокачественными моноклональными Т-лимфоцитами. Чаще болеют взрослые в возрасте от 55 до 60 лет, годовая заболеваемость составляет около 0,5 на 100 тыс. человек. Грибовидный микоз, синдром Сезари и СD30+ лимфопролиферативные заболевания являются основными подтипами ТКЛК. На сегодняшний день ТКЛК имеют сложную концепцию этиопатогенеза, диагностики, терапии и прогноза. В статье представлены обобщенные данные по этой проблеме.
Об авторах
О. М. Демина
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева» Минздрава России.
Россия
Ольга Михайловна Демина.
117997 Москва, ул. Саморы Машела, 1.
Россия
Ольга Михайловна Демина.
117997 Москва, ул. Саморы Машела, 1.
О. Е. Акилов
Клиника кожных лимфом, Университет Питтсбурга.
Соединённые Штаты Америки
15213 Питтсбург, Пятая авеню, 3601.
Соединённые Штаты Америки
15213 Питтсбург, Пятая авеню, 3601.
А. Г. Румянцев
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева» Минздрава России.
Россия
117997 Москва, ул. Саморы Машела, 1.
Россия
117997 Москва, ул. Саморы Машела, 1.
Список литературы
1. Edelson R.L. Outsmarting cutaneous T-cell lymphoma cells by decoding the language they speak: focusing past and present insights on future prospects. Clin Lymphoma Myeloma Leuk 2010;10(Suppl 2):S59–62. DOI: 10.3816/CLML.2010.s.008. PMID: 20826398.
2. Edelson R.L. Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol 1980;2(2):89–106. PMID: 6988470.
3. Rodd A.L., Ververis K., Karagiannis T.C. Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors. Lymphoma 2012;2012:1–10. DOI: 10.1155/2012/290685.
4. Lauenborg B., Christensen L., Ralfkiaer U. et al. Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma. Oncotarget 2015;6(17):15235–15249. DOI: 10.18632/oncotarget.3837. PMID: 25915535.
5. Litvinov I.V., Netchiporouk E., Cordeiro B. et al. Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma. Oncoimmunology 2014;3(11):e970025. DOI: 10.4161/21624011.2014.970025.PMID: 25941598.
6. Ponte P., Serrão V., Apetato M. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J Eur Acad Dermatol Venereol 2010;24(6):716–21. OI: 10.1111/j.1468-3083.2009.03500.x. PMID: 19929938.
7. Willemze R., Jaffe E.S., Burg G. et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105(10):3768–85. DOI: 10.1182/blood-2004-09-3502. PMID: 15692063.
8. Bradford P.T., Devesa S.S., Anderson W.F., Toro J.R. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009;113(21):5064–73. DOI: 10.1182/blood-2008-10-184168. PMID: 19279331.
9. Willemze R. Cutaneous T-cell lymphoma: epidemiology, etiology, and classification. Leuk Lymphoma 2003;44(Suppl 3):S49–54. PMID: 15202525.
10. Gómez Venegas Á.A., Vargas Rubio R.D. Unusual involvement in mycosis fungoides: Duodenal papilla. Rev Esp Enferm Dig 2016;108(8):513–6. DOI: 10.17235/reed.2015.3831/2015. PMID: 26652167.
11. Devata S., Wilcox R.A. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. Am J Clin Dermatol 2016;17(3):225–37. DOI: 10.1007/s40257-016-0177-5. PMID: 26923912.
12. Aderhold K., Carpenter L., Brown K., Donato A. Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified: A Rapidly Progressive Variant of Cutaneous T-Cell Lymphoma. Case Rep Oncol Med 2015;2015:429068. DOI: 10.1155/2015/429068. PMID: 26380134.
13. Cutaneous T-cell lymphoma. In: Bolognia J., Jorizzo J., Rapini R. Dermatology. St. Louis, Mo, USA: Mosby/Elsevier, 2008. P. 2017–2036.
14. Olsen E., Vonderheid E., Pimipinell E. et al. Revisions to the staging and classification of MF and SS: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of research and Treatment of Cancer (EORTC). Blood 2007;110(6):1713–22. DOI: 10.1182/blood-2007-03-055749. PMID: 17540844.
15. Campbell J.J., Clark R., Watanabe R., Kupper T.S. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010;116(5):767–71. DOI: 10.1182/blood-2009-11-251926. PMID: 20484084.
16. Väkevä L., Niittyvuopio R., Leppä S. et al. Allogeneic Haematopoietic Stem Cell Transplantation for Patients with Cutaneous T-cell Lymphoma. Acta Derm Venereol 2016;96(6):816–7. DOI: 10.2340/00015555-2362. PMID: 26864630.
17. Jankowska-Konsur А., Kobierzycki C., Reich A. et al. Expression of SATB1, MTI/II and Ki-67 in Mycosis Fungoides. Anticancer Res 2016;36(1):189–97. PMID: 26722043.
18. Jawed S.I., Myskowski P.L., Horwitz S. et al. Primary cutaneous Tcell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 2014;70(2):205.e1–16. DOI: 10.1016/j.jaad.2013.07.049. PMID: 24438969.
19. Moyal L., Feldbaum N., Goldfeiz N. et al. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin. PLoS One 2016;11(1):e0146115. DOI: 10.1371/journal.pone.0146115. PMID: 26752418.
20. Poligone B. Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma. Core Evid 2011;6:1–12. DOI: 10.2147/CE.S9084. PMID: 21468238.
21. Girardi M., Edelson R.L. Cutaneous Tcell lymphoma: pathogenesis and treatment. Oncology (Williston Park) 2000;14(7):1061–70. PMID: 10929591.
22. Krejsgaard T., Kopp K., Ralfkiaer E. et al. A novel xenograft model of cutaneous T-cell lymphoma. Exp Dermatol 2010;19(12):1096–102. DOI: 10.1111/j.1600-0625.2010.01138.x. PMID: 20629733.
23. Hameetman L., van der Fits L., Zout-man W.H. et al. EPHA4 is overexpressed but not functionally active in Sézary syndrome. Oncotarget 2015;6(31):31868–76. DOI: 10.18632/oncotarget.5573. PMID: 26376612
24. Benjamin Chase A., Markel K., Tawa M.C. Optimizing Care and Compliance for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel. Clin J Oncol Nurs 2015;19(6):E131–9. DOI: 10.1188/15.CJON.E131-E139. PMID: 26583648.
25. Foo S.H., Shah F., Chaganti S. et al. Unmasking mycosis fungoides/Sézary syndrome from preceding or co-existing benign inflammatory dermatoses requiring systemic therapies: patients frequently present with advanced disease and have an aggressive clinical course. Br J Dermatol 2016;174(4):901–4. DOI: 10.1111/bjd.14238. PMID: 26479768.
26. LeBlanc R.E., Tavallaee M., Kim Y.H. et al. Useful Parameters for Distinguishing Subcutaneous Panniculitis-like T-Cell Lymphoma From Lupus Erythematosus Panniculitis. Am J Surg Pathol 2016;40(6):745–54. DOI: 10.1097/PAS.0000000000000596. PMID: 26796503.
27. Pankratov O., Gradova S., Tarasevich S., Pancratov V. Poikilodermatous mycosis fungoides: clinical and histopathological analysis of a case and literature review. Acta Dermatovenerol Alp Pannonica Adriat 2015;24(2):37–41. DOI: 10.15570/actaapa.2015.10. PMID: 26086166.
28. Sarveswari K.N., Yesudian P. The conundrum of parapsoriasis versus patch stage of mycosis fungoides. Indian J Dermatol Venereol Leprol 2009;75:229–35. DOI: 10.4103/0378-6323.51239. PMID: 19439874.
29. Eklund Y., Aronsson A., Schmidtchen A. et al. Mycosis Fungoides: A Retrospective Study of 44 Swedish Cases. Acta Derm Venereol 2016;96(5):669–73. DOI: 10.2340/00015555-2337. PMID: 26778803.
30. Sarantopoulos G.P., Palla B., Said J. et al. Mimics of cutaneous lymphoma: Report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol 2013;139(4):536–51. DOI: 10.1309/AJCPX4BXTP2QBRKO. PMID: 23525620.
31. Smedby K.E., Vajdic C.M., Falster M. et al. Autoimmune disorders and risk of nonHodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood 2008; 111(8):4029–38. DOI: 10.1182/blood-2007-10-119974. PMID: 18263783.
32. Kash N., Massone C., Fink-Puches R. et al. Phenotypic Variation in Different Lesions of Mycosis Fungoides Biopsied Within a Short Period of Time From the Same Patient. Am J Dermatopathol 2016;38(7):541–5. DOI: 10.1097/DAD.0000000000000493. PMID: 26885605.
33. Smoller B.R., Bishop K., Glusac E. et al. Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Am J Surg Pathol 1995;19(12):1423–30. PMID: 7503364.
34. Bosisio F.M., Cerroni L. Expression of Tfollicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas. Am J Dermatopathol 2015;37(2):115–21. DOI: 10.1097/DAD.0000000000000258. PMID: 25406852.
35. Smoller B.R. Mycosis fungoides: what do/do not we know? J Cutan Pathol 2008;35(Suppl 2):35–9. DOI: 10.1111/j.1600-0560.2008.01120.x. PMID: 18976417.
36. Girardi M., Heald P.W., Wilson L.D. The pathogenesis of mycosis fungoides. New Engl J Med 2004;350(19):1978–88. DOI: 10.1056/NEJMra032810. PMID: 15128898.
37. Lebas E., Libon F., Nikkels A.F. Koebner Phenomenon and Mycosis Fungoides. Case Rep Dermatol 2015;7(3):287–291. DOI: 10.1159/000440856. PMID: 26557075.
38. Lee C.S., Ungewickell A., Bhaduri A. et al. Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated LncRNAs and novel transcripts. Blood 2012;120(16):3288–97. DOI: 10.1182/blood-2012-04-423061. PMID: 22936659.
39. Maj J., Jankowska-Konsur A.M., Hałoń A. et al. Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides. Postepy Dermatol Alergol 2015;32(6):437–42. DOI: 10.5114/pdia.2015.48034.PMID: 26755907.
40. Nahidi Y., Meibodi N.T., Ghazvini K. et al. Evaluation of the Association between Epstein–Barr virus and Mycosis Fungoides. Indian J Dermatol 2015;60(3):321. DOI: 10.4103/0019-5154.156423. PMID: 26120176.
41. Wong H.K., Mishra A., Hake T., Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 2011;155(2):150–166. DOI: 10.1111/j.1365-2141.2011.08852. PMID: 21883142.
42. Booken N., Gratchev A., Utikal J. et al. Sezary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia 2008;22(2):393–9. DOI: 10.1038/sj.leu.2405044. PMID: 18033314.
43. da Silva Almeida A.C., Abate F., Khiabanian H. et al. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nat Genet 2015;47(12): 1465–70. DOI: 10.1038/ng.3442. PMID: 26551667.
44. Dulmage B.O., Akilov O., Vu J.R. et al. Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma. Oncotarget 2015. DOI: 10.18632/oncotarget.5742.
45. Gallardo F., Sandoval J., Díaz-Lagares A. et al. Notch1 Pathway Activation Results from the Epigenetic Abrogation of NotchRelated MicroRNAs in Mycosis Fungoides. J Invest Dermatol 2015;135(12):3144–52. DOI: 10.1038/jid.2015.328. PMID: 26302069.
46. Katona T.M., Smoller B.R., Webb A.L. et al. Expression of PTEN in mycosis fungoides and correlation with loss of heterozygosity. Am J Dermatopathol 2013;35(5):555–60. DOI: 10.1097/DAD.0b013e318276cc68. PMID: 23715078.
47. Kitadate A., Ikeda S., Teshima K. et al. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas. Oncogene 2016;35(28):3692–704. DOI: 10.1038/onc.2015.435. PMID: 26640145.
48. Krejsgaard T., Ralfkiaer U., Clasen-Linde E. et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol 2011;131(6):1331–8. DOI: 10.1038/jid.2011.27. PMID: 21346774.
49. McGirt L.Y., Jia P., Baerenwald D.A. et al. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood 2015;126(4):508–19. DOI: 10.1182/blood-2014-11-611194. PMID: 26082451.
50. Shareef M.M., Elgarhy L.H., Wasfy Rel-S. Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphoma and Sézary Syndrome. Asian Pac J Cancer Prev 2015;16(13):5359–64. DOI: 10.7314/APJCP.2015.16.13.5359. PMID: 26225678.
51. Sibbesen N.A., Kopp K.L., Litvinov I.V. et al. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Oncotarget 2015; 6(24): 20555–20569. DOI: 10.18632/oncotarget.4111. PMID: 26244872.
52. Tensen C.P. PLCG1 Gene Mutations in Cutaneous T-Cell Lymphomas Revisited. J Invest Dermatol 2015;135(9):2153–4. DOI: 10.1038/jid.2015.221. PMID: 26269406.
53. Ungewickell A., Bhaduri A., Rios E. et al. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nat Genet 2015;47(8):1056–60. DOI: 10.1038/ng.3370. PMID: 26258847.
54. Wang L., Ni X., Covington K.R. et al. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 2015;47(12):1426–34. DOI: 10.1038/ng.3444. PMID: 26551670.
55. Woollard W.J., Kalaivani N.P., Jones C.L. et al. Independent Loss of Methylthioadenosine Phosphorylase (MTAP) in Primary Cutaneous T-Cell Lymphoma. J Invest Dermatol 2016;136(6):1238–46. DOI: 10.1016/j.jid.2016.01.028. PMID: 26872600.
56. Krejsgaard T., Litvinov I.V., Wang Y. et al. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood 2013;122(6):943–50. DOI: 10.1182/blood-2013-01-480889. PMID: 23801634.
57. Marzec M., Liu X., Kasprzycka M. et al. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood 2008;111(4):2181–9. DOI: 10.1182/blood-2007-06-095182. PMID: 18025151.
58. Booken N., Gratchev A., Utikal J. et al. Sezary syndrome is a unique cutaneous Tcell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia 2008;22(2):393–99. DOI: 10.1038/sj.leu.2405044. PMID: 18033314.
59. Lee H.S., Suh K.S., Lee D.Y. et al. Cutaneous Lymphoma in Korea: A Nationwide Retrospective Study. Acta Derm Venereol 2016;96(4):535–9. DOI: 10.2340/00015555-2283. PMID: 26560051.
60. Manso R., Martínez-Magunacelaya N., Eraña-Tomás I. et al. Mycosis fungoides progression could be regulated by microRNAs. PLoS One 2018;13(6):e0198477. DOI: 10.1371/journal.pone.0198477. PMID: 29894486.
61. Picchio M.C., Scala E., Pomponi D. et al. CXCL13 is highly produced by Sezary cells and enhances their migratory ability via a synergistic mechanism involving CCL19 and CCL21 chemokines. Cancer Res 2008;68(17):7137–46. DOI: 10.1158/0008-5472.CAN-08-0602. PMID: 18757429.
62. Zhang Y., Zhao H., Zhao D. et al. SDF-1/CXCR4 axis in myelodysplastic syndromes: correlation with angiogenesis and apoptosis. Leuk Res 2012;36(3):281–6. DOI: 10.1016/j.leukres.2011.06.017. PMID: 21802140.
63. Wu X., Lonsdorf A.S., Hwang S.T. Cutaneous T cell lymphoma: roles for chemokines and chemokines receptors. J Invest Dermatol 2009;129(5):1115–9. DOI: 10.1038/jid.2009.45. PMID: 19242508.
64. Choi J., Goh G., Walradt T. et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet 2015;47(9):1011–9. DOI: 10.1038/ng. 3356. PMID: 26192916.
65. Zhan H.L., Gao X., Zhou X.F. et al. Presence of tumourinfiltrating FOXP3+ lymphocytes correlates with immature tumour angiogenesis in renal cell carcinomas. Asian Pac J Cancer Prev 2012;13(3): 867–72. DOI: 10.7314/APJCP.2012.13.3.867. PMID: 22631663.
66. Narducci M.G., Scala E., Bresin A. et al. Skin homing of Sezary cells involves SDF-1–CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood 2006;107:1108–5. DOI: 10.1182/blood-2005-04-1492. PMID: 16204308.
67. Guenova E., Ignatova D., Chang Y.T. et al. Expression of CD164 on Malignant T cells in Sézary Syndrome. Acta Derm Venereol 2016;96(4):464–7. DOI: 10.2340/00015555-2264. PMID: 26524186.
68. Wysocka M., Kossenkov A.V., Benoit B.M. et al. CD164 and FCRL3 are highly expressed on CD4+CD26−T cells in Sezary syndrome patients. J Invest Dermatol 2014;134(1):229–36. DOI: 10.1038/jid.2013.279. PMID: 23792457.
69. Jain S., Stroopinsky D., Yin L. et al. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood 2015;126(3):354–62. DOI: 10.1182/blood-2015-02-628149. PMID: 26048911.
70. Karpova M., Fujii K., Jenni D. et al. Evaluation of lymphangiogenic markers in Sezary syndrome. Leuk Lymphoma 2011;52(3):491–501. DOI: 10.3109/10428194.2010.517877. PMID: 20846094.
71. Krejsgaard T., Vetter-Kauczok C.S., Woetmann A. et al. Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006;20(10):1759–66. DOI: 10.1038/sj.leu.2404350. PMID: 16932349.
72. Pedersen I., Willerslev-Olsen A., VetterKauczok C. et al. Vascular endothelial growth factor receptor-3 expression in mycosis fungoides. Leuk Lymphoma 2013;54(4):819–26. DOI: 10.3109/10428194.2012.726720. PMID: 22946664.
73. Fletcher C.L., Orchard G.E., Hubbard V. et al. CD30(+) cutaneous lymphoma in association with atopic eczema. Arch Dermatol 2004;140:449–54. DOI: 10.1001/archderm.140.4.449. PMID: 15096373.
74. Pousa C.M., Nery N.S., Mann D. et al. Granulomatous mycosis fungoides – a diagnostic challenge. An Bras Dermatol 2015;90(4):554–6. DOI: 10.1590/abd1806-4841.20153460. PMID: 26375225.
75. Mirvish E.D., Pomerantz R.G., Geskin L.J. Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol 2011;64(2):423–31. DOI: 10.1016/j.jaad.2009.11.692. PMID: 20692726.
76. Willerslev-Olsen A., Krejsgaard T., Lin-dahl L.M. et al. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood 2016;127(10):1287–96. DOI: 10.1182/blood-2015-08-662353. PMID: 26738536.
77. Talpur R., Sui D., Gangar P. et al. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides. Clin Lymphoma Myeloma Leuk 2016;16(1):49–56. DOI: 10.1016/j.clml.2015.11.010. PMID: 26702474.
78. Yao S., Zhu Y., Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 2013;12(2):130–46. DOI: 10.1038/nrd3877. PMID: 23370250.
79. Mirvish J.J., Pomerantz R.G., Falo L.D.Jr., Geskin L.J. Role of infectious agents in cutaneous T-cell lymphoma: facts and controversies. Clin Dermatol 2013;31(4):423–31. DOI: 10.1016/j.clindermatol.2013.01.009. PMID: 23806159.
80. Nagasawa T., Takakuwa T., Takayama H. et al. Fas gene mutations in mycosis fungoides: Analysis of laser capture-microdissected specimens from cutaneous lesions. Oncology 2004;67:130–4. DOI: 10.1159/000080999. PMID: 15539917.
81. Hughes C.F., Newland K., McCormack C. et al. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers. Australas J Dermatol 2016;57(3):182–91. DOI: 10.1111/ajd.12349. PMID: 25988337.
82. Kirsch I.R., Watanabe R., O’Malley J.T. et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med 2015;7(308):308ra158. DOI: 10.1126/scitranslmed.aaa9122. PMID: 26446955.
83. Sidiropoulos K.G., Martinez-Escala M.E., Yelamos O. et al. Primary cutaneous T-cell lymphomas: a review. J Clin Pathol 2015;68(12):1003–10. DOI: 10.1136/jclinpath-2015-203133. PMID: 26602417.
84. Alanteri E., Usmani S., Marafi F. et al. The role of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with mycosis fungoides. Indian J Nucl Med 2015;30(3):199–203. DOI: 10.4103/0972-3919.158527. PMID: 26170561.
85. Gallardo F., García-Muret M.P., Servitje O. et al. Cutaneous lymphomas showing prominent granulomatous component: clinicopathological features in a series of 16 cases. J Eur Acad Dermatol Venereol 2009;23:639–47. DOI: 10.1111/j.1468-3083.2008.03020.x. PMID: 19207677.
86. Aggarwal S., Topaloglu H., Kumar S. Systematic Review of Burden of Cutaneous T-Cell Lymphoma. Value Health 2015;18(7):A438. DOI: 10.1016/j.jval.2015.09.1065. PMID: 26532464.
87. Gibson J.F., Huang J., Liu K.J. et al. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. J Am Acad Dermatol 2016;74(5):870–7. DOI: 10.1016/j.jaad.2015.12.018. PMID: 26874819.
88. Agar N.S., Wedgeworth E., Crichton S. et al. Survival and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010;28(31):4730–9. DOI: 10.1200/JCO.2009.27.7665. PMID: 20855822.
89. Katona T.M., O’Malley D.P., Cheng L. et al. Loss of heterozygosity analysis identifies genetic abnormalities in mycosis fungoides and specific loci associated with disease progression. Am J Surg Pathol 2007;31(10):1552–6. DOI: 10.1097/PAS.0b013e3180408d76. PMID: 17895757.
90. Ahmed S.K., Grams M.P., Locher S.E. et al. Adaptation of the Stanford technique for treatment of bulky cutaneous T-cell lymphoma of the head. Pract Radiat Oncol 2016; 6(3):183–6. DOI: 10.1016/j.prro.2015.10.021. PMID: 26712465.
91. Chmielowska E., Studziński M., Giebel S. et al. Follow-up of patients with mycosis fungoides after interferon α2b treatment failure. Postepy Dermatol Alergol 2015;32(2):67–72. DOI: 10.5114/pdia.2014.40941. PMID: 26015774.
92. Talpur R., Bassett R., Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol 2008;159(1):105–12. DOI: 10.1111/j.1365-2133.2008.08612.x. PMID: 18489588.
93. Child F., Ortiz-Romero P.L., Alvarez R. et al. Phase II Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Mycosis Fungoides/Sézary Syndrome. Br J Dermatol 2016;175(1):80–8. DOI: 10.1111/bjd.14427. PMID: 26836950.
94. Fujii K. New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma. Front Oncol 2018;8:198. DOI: 10.3389/fonc.2018.00198. PMID: 29915722.
95. Virmani P., Zain J., Rosen S.T. et al. Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome. Dermatol Clin 2015;33(4):807–18. DOI: 10.1016/j.det.2015.05.014. PMID: 26433851.
96. Wilcox R.A. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91(1):151–65. DOI: 10.1002/ajh.24233. PMID: 26607183.
97. Nguyen C.V., Bohjanen K.A. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma. Dermatol Clin 2015;33(4): 683–896. DOI: 10.1016/j.det.2015.05.004. PMID: 26433841.
98. Rook A.H., Gelfand J.M., Wysocka M. et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood 2015;126(12):1452–61. DOI: 10.1182/blood-2015-02-630335. PMID: 26228486.
99. Goddard A.L., Vleugels R.A., LeBoeuf N.R. et al. Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet with Low-Dose, High Dose-Rate Brachytherapy. JAMA Dermatol 2015;151(12):1354–7. DOI: 10.1001/jamadermatol.2015.3028. PMID: 26397774.
100. Tandberg D.J., Craciunescu O., Kelsey C.R. Radiation Therapy for Cutaneous T-Cell Lymphomas. Dermatol Clin 2015;33(4):703–13. DOI: 10.1016/j.det.2015.05.006. PMID: 26433843.
101. Elsayad K., Kriz J., Moustakis C. et al. Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma. Int J Radiat Oncol Biol Phys 2015;93(5):1077–86. DOI: 10.1016/j.ijrobp.2015.08.041. PMID: 26581145.
102. Gamsiz H., Beyzadeoglu M., Sager O. et al. Evaluation of mycosis fungoides management by total skin electron beam therapy with “translational technique”. J BUON 2015;20(4):1124–31. PMID: 26416066.
103. Salva K.A., Kim Y.H., Rahbar Z., Wood G.S. Epigenetically Enhanced PDT Induces Significantly Higher Levels of Multiple Extrinsic Pathway Apoptotic Factors than Standard PDT, Resulting in Greater Extrinsic and Overall Apoptosis of Cutaneous T-cell Lymphoma. Photochem Photobiol 2018 [Epub ahead of print]. DOI: 10.1111/php.12925. PMID: 29675945.
104. Salva K.A., Wood G.S. Epigenetically Enhanced Photodynamic Therapy (ePDT) is Superior to Conventional Photodynamic Therapy for Inducing Apoptosis in Cutaneous T-Cell Lymphoma. Photochem Photobiol 2015;91(6):1444–51. DOI: 10.1111/php.12521. PMID: 26302991.
105. Wu J., Wood G.S. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol 2011;147(4):443–50. DOI: 10.1001/archdermatol.2010.376. PMID: 21173302.
106. Huen A.O., Kim E.J. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. Dermatol Clin 2015;33(4):715–29. DOI: 10.1016/j.det.2015.05.007. PMID: 26433844.
107. Kato Y., Egusa C., Maeda T. et al. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation. J Dermatol Sci 2016;81(1):17–25. DOI: 10.1016/j.jdermsci.2015.10. PMID: 26596218.
108. Marciano D.P., Kuruvilla D.S., Pascal B.D. et al. Identification of Bexarotene as a PPARγ Antagonist with HDX. PPAR Res 2015;2015:254560. DOI: 10.1155/2015/254560. PMID: 26451138.
109. Rodriguez Suarez S., Pamies Andreu E., Muñiz Grijalvo O. et al. Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma. Med Clin (Barc) 2016;146(3):117–20. DOI: 10.1016/j.medcli.2015.07.017. PMID: 26688184.
110. Zinzani P.L., Bonthapally V., Huebner D. et al. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. Crit Rev Oncol Hematol 2016;99:228–40. DOI: 10.1016/j.critrevonc.2015.12.2018. PMID: 26811014.
111. Chung C.G., Poligone B. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy. Curr Hematol Malig Rep 2015;10(4):468–76. DOI: 10.1007/s11899-015-0293-y. PMID: 26626770.
112. Valdez B.C., Brammer J.E., Li Y. et al. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J 2015;5:e357. DOI: 10.1038/bcj.2015.83. PMID: 26473529.
113. Scarisbrick J.J., Prince H.M., Vermeer M.H. et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 2015;33(32):3766–73. DOI: 10.1200/JCO.2015.61.7142. PMID: 26438120.
114. Martinez-Escala M.E., Posligua A.L., Wickless H. et al. Progression of undiagnosed cutaneous lymphoma after anti–tumor necrosis factor-alpha therapy. J Am Acad Dermatol 2018;78(6):1068–76. DOI: 10.1016/j.jaad.2017.12.068. PMID: 29307643.
115. Hosing C., Bassett R., Dabaja B. et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol 2015;26(12):2490–5. DOI: 10.1093/annonc/mdv473. PMID: 26416896.
116. de Masson A., Beylot-Barry M., Bouaziz J.D. et al. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French society of bone marrow transplantation and French study group on cutaneous lymphomas. Haematologica 2014;99(3):527–34. DOI: 10.3324/haematol.2013.098145. PMID: 24213148.
117. Lechowitcz M.J., Lazarus H.M., Carreras J. et al. Allogenic hematopoietic cell transplantation for mycosis fungoides and Sézary syndrome. Bone Marrow Transplant 2014;49(11):1360–5. DOI: 10.1038/bmt.2014.161. PMID: 25068422.
118. Zic J.A. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome. Dermatol Clin 2015;33(4):765–76. DOI: 10.1016/j.det.2015.05.011. PMID: 26433848.
119. Oka T., Sugaya M., Cury-Martins J. et al. Hematopoietic stem cell transplantation for cutaneous T-cell lymphoma: Summary of 11 cases from two facilities in Japan and Brazil. J Dermatol 2016;43(6): 638–42. DOI: 10.1111/1346-8138.13199. PMID: 26602996.
120. Rozati S., Kim Y.H. Experimental treatment strategies in primary cutaneous T-cell lymphomas. Curr Opin Oncol 2016;28(2): 166–71. DOI: 10.1097/CCO.0000000000000272. PMID: 26844985.
121. Witzig T.E., Reeder C., Han J.J. et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood 2015;126(3):328–35. DOI: 10.1182/blood-2015-02-629543. PMID: 25921059.
122. Jankowska-Konsur A., Kobierzycki C., Reich A. et al. Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas. Anticancer Res 2015;35(11):6017–26. PMID: 26504025.
123. Desai M., Liu S., Parker S. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sezary syndrome in the southeastern United States: a single-institution cohort. J Am Acad Dermatol 2015;72(2):276–85. DOI: 10.1016/j.jaad.2014.10.019. PMID: 25458019.
Рецензия
Для цитирования:
Демина О.М., Акилов О.Е., Румянцев А.Г. Т-клеточные лимфомы кожи: современные данные патогенеза, клиники и терапии. Онкогематология. 2018;13(3):25-38. https://doi.org/10.17650/1818-8346-2018-13-3-25-38
For citation:
Demina O.M., Akilov O.E., Rumyantsev A.G. Cutaneous T-cell lymphomas: modern data of pathogenesis, clinics and therapy. Oncohematology. 2018;13(3):25-38. (In Russ.) https://doi.org/10.17650/1818-8346-2018-13-3-25-38
Просмотров:
16422
Послать статью по эл. почте 